Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial

BACKGROUND: Tyrosine kinase inhibitors remain a cornerstone in managing metastatic clear cell renal cell carcinoma (RCC). The 4 weeks on/2 weeks off intermittent sunitinib schedule could result in rebound angiogenesis and tumor progression in the 2-week rest period. We propose using bevacizumab duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazarbashi, Shouki, Alzahrani, Ahmed, Aljubran, Ali, Elshenawy, Mahmoud, Gad, Ahmed Mostafa, Maraiki, Fatima, Alzannan, Noura, Elhassan, Tusneem, Badran, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166178/
https://www.ncbi.nlm.nih.gov/pubmed/36648325
http://dx.doi.org/10.1093/oncolo/oyac261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166178/
https://www.ncbi.nlm.nih.gov/pubmed/36648325
http://dx.doi.org/10.1093/oncolo/oyac261

Ejemplares similares